Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of “Buy” from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received an average recommendation of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $197.00.

A number of research firms recently issued reports on KRYS. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Stifel Nicolaus raised their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. William Blair raised Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Chardan Capital upped their price objective on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $175.64 on Tuesday. The firm has a 50 day moving average price of $180.83 and a 200 day moving average price of $181.79. The stock has a market cap of $5.05 billion, a P/E ratio of 99.23 and a beta of 0.82. Krystal Biotech has a 52-week low of $99.00 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period in the previous year, the company posted ($0.67) earnings per share. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. Analysts predict that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 14.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. Teachers Retirement System of The State of Kentucky boosted its holdings in Krystal Biotech by 198.2% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company’s stock valued at $1,640,000 after purchasing an additional 5,989 shares during the period. Geode Capital Management LLC boosted its stake in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after buying an additional 11,411 shares during the period. Main Management ETF Advisors LLC bought a new stake in shares of Krystal Biotech in the third quarter valued at approximately $706,000. Zacks Investment Management grew its position in Krystal Biotech by 5.6% during the third quarter. Zacks Investment Management now owns 9,447 shares of the company’s stock worth $1,720,000 after buying an additional 504 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Krystal Biotech by 15.1% during the 3rd quarter. Wellington Management Group LLP now owns 12,680 shares of the company’s stock worth $2,308,000 after acquiring an additional 1,660 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).